Wells Fargo Downgrades Edwards Lifesciences (EW) to Market Perform; Near-Term Uncertainty And Valuation
Tweet Send to a FriendGet Alerts EW Hot Sheet
Price: $65.18 -0.82%
Rating Summary:
11 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 15 | New: 13
Rating Summary:
11 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 15 | New: 13
Trade EW Now!
Wells Fargo downgraded Edwards Lifesciences (NYSE: EW) from Outperform to Market Perform, price target range $81-83 from $91-93.
Wells analyst says, "While we remain bullish on the long-term potential of transcatheter aortic valve implants (TAVI) and we expect EW to maintain its leadership position in this attractive space, we are downgrading our rating on EW mainly due to (1) near-term uncertainty in the uptake of EW’s Sapien in the U.S. (2) poor visibility on Sapien sales outside the U.S. (OUS); and (3) valuation. We reduced our OUS TAVI estimates due to a sharp deceleration in OUS Sapien growth in Q4 2011, which results in a revised valuation range of $81-83...We are lowering our 2012 sales estimate by $48MM to $1,946MM."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $80.67 yesterday, with a 52 week range of $61.59-$91.82.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Wells analyst says, "While we remain bullish on the long-term potential of transcatheter aortic valve implants (TAVI) and we expect EW to maintain its leadership position in this attractive space, we are downgrading our rating on EW mainly due to (1) near-term uncertainty in the uptake of EW’s Sapien in the U.S. (2) poor visibility on Sapien sales outside the U.S. (OUS); and (3) valuation. We reduced our OUS TAVI estimates due to a sharp deceleration in OUS Sapien growth in Q4 2011, which results in a revised valuation range of $81-83...We are lowering our 2012 sales estimate by $48MM to $1,946MM."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $80.67 yesterday, with a 52 week range of $61.59-$91.82.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Wedbush Downgrades salesforce.com (CRM) to Neutral
- UPDATE: Exane BNP Paribas Downgrades BlackBerry (BBRY) to Underperform; Analyst Says Profit 'Drying Up'
- Deutsche Bank Downgrades Signet Jewelers (SIG) to Hold
Create E-mail Alert Related Categories
DowngradesRelated Entities
Wells Fargo
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
